Kamala Maddali

Kamala Maddali
Kamala Maddali, DVM, PhD Vice President, Biopharma Collaborations & Companion Diagnostics, Cancer Genetics Dr. Maddali’s mantra for leadership is to “spread some sunshine” by being passionate and positive about her commitment to patient’s health through her collaborative mindset in precision/personalized medicine. Dr. Maddali is very committed to saving lives, to empower those affected by cancer, and to inspire younger generations to stay committed to healthcare education and be the future of global community health. Dr. Maddali’s cross collaborative mindset comes from her unique professional background and education. She holds a PhD in Pharmacology from the University of Missouri-Columbia and a …
Kamala Maddali, DVM, PhD

Vice President, Biopharma Collaborations & Companion Diagnostics, Cancer Genetics

Dr. Maddali’s mantra for leadership is to “spread some sunshine” by being passionate and positive about her commitment to patient’s health through her collaborative mindset in precision/personalized medicine. Dr. Maddali is very committed to saving lives, to empower those affected by cancer, and to inspire younger generations to stay committed to healthcare education and be the future of global community health.

Dr. Maddali’s cross collaborative mindset comes from her unique professional background and education. She holds a PhD in Pharmacology from the University of Missouri-Columbia and a DVM Veterinary Medicine from Acharya N.G. Ranga Agricultural University in India. Dr. Maddali is a native of Andhra Pradesh, India.

While at Merck, Dr. Maddali played a pivotal role as a biomarker scientist understanding the various pharmacological and toxic effects of investigational drugs across multiple therapeutic areas in oncology, neurology and obesity disorders. She also has extensive experience as a chief scientific commercial liaison for precision medicine at top-tier central laboratories and reference laboratories, including Quintiles and Quest Diagnostics.

At Cancer Genetics, she has initiated a biopharma collaboration campaign, implementing strategic initiatives to foster positive growth of the company through the provision of high-quality, innovative, responsive services. Her vision is to ensure that the patient’s voice is heard and her goal is to help patients and pharma partners implement the right test for the right patient and innovate the right drugs for improving global community health.

As an ongoing warrior with Multiple Sclerosis, Dr. Maddali’s vision includes “Educating global communities with hope from science and innovation” which will foster awareness towards early cancer diagnosis and prevention. She is a board member for several US based patient advocacy organizations like “Paltown”, “Cancer NJ”, a South Asian cancer patient advocacy organization working to foster knowledge about cancer diagnosis and prevention, and is a scientific advisor to “Beat Cancer,” which works to help prevent cancer through lifestyle changes.

Dr. Maddali also empowers students as a scientific educational mentor and helps them to successfully navigate their educational goals by staying committed to healthcare. Dr. Maddali was the 2016 Healthcare Heroes Finalist Award for “Innovation-Individual” category at NJBIZ. Dr. Maddali received many awards focused on female empowerment from several organizations in USA.

Dr. Maddali serves as a Vice Chair for the Women in Bio (WIB) Philadelphia chapter. The Women in Bio organization promotes careers, leadership, and entrepreneurship for women in the life sciences.
See more

Articles: Kamala Maddali

AI: The Time is Right for a New Pharma Business Model

Opinion / Dr Kamala Maddali looks at how artificial intelligence is currently being utilized across the healthcare spectrum and why the time is now for Big Pharma to adopt this technology more fully.   The beauty of artificial intelligence is that it allows one to assess both forest and tree.   A case in point. Two years…

The Impact of Next Generation Sequencing on Women-Focused Cancers

Opinion / Kamala Maddali, vice president for Biopharma Collaborations & Companion Diagnostics at Cancer Genetics, discusses what impact next generation sequencing (NGS) stands to have on cancers that affect women.   NGS technology allows for the rapid and accurate sequencing of many genes at once 2018 saw an estimated 18 million cancer cases around the world. Of…

See more